Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Acusphere, Inc. ACUS OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
36/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Acusphere, Inc. (ACUS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $3M, +33.9%/yr average growth. Net income is $54M (loss), growing at -24.6%/yr. Net profit margin is -2014.6% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $18M against $24M equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.45 (adequate). Debt-to-assets is 34.6%. Total assets: $52M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

ACUS SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACUS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ACUS: +33.9%/yr revenue is, -24.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ACUS: Debt-to-Equity (D/E) ratio 0.76 (moderate), Current ratio is 1.45 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
ACUS: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ACUS: Net profit margin is -2014.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.000001-0.00001
Volume125
Avg Volume (30D)60
Market Cap$49.00
Beta (1Y)-0.52
Share Statistics
EPS (TTM)-12.60
Shares Outstanding$4.26M
IPO Date2003-10-08
CEOWilliam I. Ramage D.Phil
Financial Highlights & Ratios
Revenue (TTM)$2.67M
Gross Profit$2.67M
EBITDA$-44.93M
Net Income$-53.73M
Operating Income$52.73M
Total Cash$26.1M
Total Debt$18.01M
Net Debt$-8.09M
Total Assets$52.02M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS00511R8549

Price Chart

Track all markets on TradingView
ACUS
Acusphere, Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.00

People Also View

LFCR
LFCR
Lifecore Biomedical, Inc.
$5.38
+3.46%
 CYTH
CYTH
Cyclo Therapeutics, Inc.
$0.72
+0.00%
 ATNX
ATNX
Athenex, Inc.
$0.20
+0.00%
 LSDI
LSDI
Lucy Scientific Discovery Inc.
$0.51
-23.29%
 MMNFF
MMNFF
MedMen Enterprises Inc.
$0.00
+9,900.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message